A Phase 1b Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GS-9820 in Subjects With Lymphoid Malignancies
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Acalisib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 16 May 2016 Status changed from active, no longer recruiting to completed.
- 04 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov
- 04 Dec 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Apr 2016 as reported by ClinicalTrials.gov